Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-669P (RNA, U6 small nuclear 669, pseudogene) is annotated as a human pseudogene homologous to U6 small nuclear RNA, but it does not produce functional RNA and is not considered a receptor, enzyme, transporter, or typical molecular target. The U6 small nuclear RNA (snRNA) itself is essential for the catalytic function of the spliceosome and is highly conserved in eukaryotes, with many genomic copies and pseudogenes[1][3]. Pseudogenes such as RNU6-669P may arise from duplication or retrotransposition events and typically lack promoter activity, are not translated, and do not fulfill canonical snRNA function. Some pseudogenes in general can regulate gene expression by acting as decoys for miRNA or RNA-binding proteins, or by generating non-coding RNAs, but there is no published evidence linking RNU6-669P to therapeutically relevant roles or disease biology[2]. There are no drugs, biomarkers, or molecular mechanisms attributed to this pseudogene, and it is not considered a therapeutic target. Key facts: - The canonical, functional molecule is U6 snRNA, a core noncoding RNA involved in mRNA splicing[1][3]. - "Pseudogene" designation (RNU6-669P) means it does not produce functional protein or RNA and should not be considered a target. - U6 snRNA pseudogenes (including RNU6-669P) are abundant in the human genome but not known to be of clinical or drug relevance[3]. - Entry is incorrect as a target: it is not a receptor, enzyme, transporter, or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 669, pseudogene (RNU6-669P).